{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:53:23Z","timestamp":1780718003156,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2023.11.052","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T11:48:00Z","timestamp":1702727280000},"page":"2553-2559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax\u00ae Rabies) administered in a simulated rabies post-exposure regimen in healthy adults"],"prefix":"10.1016","volume":"42","author":[{"given":"Sylvie","family":"Pichon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-2833","authenticated-orcid":false,"given":"Annick","family":"Moureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-8525","authenticated-orcid":false,"given":"Judith L.","family":"Kirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sheldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Guinet-Morlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada-Maria","family":"Minutello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.11.052_b0005","doi-asserted-by":"crossref","first-page":"e0003786","DOI":"10.1371\/journal.pntd.0003786","article-title":"Correction: estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.11.052_b0010","unstructured":"World Health Organization. WHO factsheet: Rabies. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies."},{"key":"10.1016\/j.vaccine.2023.11.052_b0015","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 - Recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.052_b0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11908-016-0540-y","article-title":"Human Rabies: a 2016 Update","volume":"18","author":"Jackson","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2023.11.052_b0025","unstructured":"World Health Organization. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser. 2013:1-139, back cover."},{"key":"10.1016\/j.vaccine.2023.11.052_b0030","unstructured":"Centers for Disease Control and Prevention. Pre-exposure Prophylaxis (PrEP). 2022. https:\/\/www.cdc.gov\/rabies\/prevention\/pre-exposure_vaccinations.html."},{"key":"10.1016\/j.vaccine.2023.11.052_b0035","unstructured":"Centers for Disease Control and Prevention. Rabies Postexposure Prophylaxis (PEP). 2022. https:\/\/www.cdc.gov\/rabies\/medical_care\/index.html."},{"key":"10.1016\/j.vaccine.2023.11.052_b0040","doi-asserted-by":"crossref","first-page":"2027714","DOI":"10.1080\/21645515.2022.2027714","article-title":"Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2023.11.052_b0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.15585\/mmwr.mm7118a2","article-title":"Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.11.052_b0050","series-title":"WHO Consultation on Public Health and Animal Transmissible Spongiform Encephalopathies: Epidemiology, Risk and Research Requirements","author":"World Health Organization","year":"1999"},{"key":"10.1016\/j.vaccine.2023.11.052_b0055","series-title":"European Pharmacopoeia 90","first-page":"627","article-title":"Raw materials of biological origin for the production of cell-based and gene therapy medicinal products","author":"Pharmacopoeioa","year":"2017"},{"key":"10.1016\/j.vaccine.2023.11.052_b0060","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.vaccine.2013.02.058","article-title":"A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial","volume":"31","author":"Pichon","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.052_b0065","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2013.10.043","article-title":"A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab(R) when administered according to a post-exposure regimen in healthy children and adults in China","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.052_b0070","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1016\/j.vaccine.2022.06.061","article-title":"Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study","volume":"40","author":"Quiambao","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.052_b0075","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1016\/j.vaccine.2022.06.040","article-title":"Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study","volume":"40","author":"Pichon","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.052_b0080","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1371\/journal.pntd.0000595","article-title":"Rabies-specific antibodies: measuring surrogates of protection against a fatal disease","volume":"4","author":"Moore","year":"2010","journal-title":"PLOS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.11.052_b0085","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.11.052_b0090","unstructured":"World Health Organization. Expert Consultation on Rabies: second report. 2013."},{"key":"10.1016\/j.vaccine.2023.11.052_b0095","unstructured":"Advisory Committee on Immunization Practices (ACIP). Human Rabies Prevention \u2014United States, 1999. Morbidity and mortality weekly report: Centers for Disease Control and Prevention; 1999."},{"key":"10.1016\/j.vaccine.2023.11.052_b0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2023.11.052_b0105","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1038\/s41598-020-66754-8","article-title":"Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition test","volume":"10","author":"Timiryasova","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.11.052_b0110","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/s41598-022-10281-1","article-title":"Inhibitory effect of concomitantly administered rabies immunoglobulins on the immunogenicity of commercial and candidate human rabies vaccines in hamsters","volume":"12","author":"Bernard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.11.052_b0115","first-page":"1825","article-title":"Rabies immune globulin (human)","volume":"217","author":"Loofbourow","year":"1971","journal-title":"Clin Trials Dose Determination Jama"},{"key":"10.1016\/j.vaccine.2023.11.052_b0120","first-page":"1","article-title":"Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2023.11.052_b0125","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/21645515.2017.1307483","article-title":"Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study","volume":"13","author":"Sampath","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.11.052_b0130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14760584.2018.1473765","article-title":"Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis","volume":"17","author":"Preiss","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.11.052_b0135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/21645515.2019.1656967","article-title":"Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2\/3 trial","volume":"16","author":"Matson","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.11.052_b0140","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1080\/21645515.2020.1854000","article-title":"Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure","volume":"17","author":"Hobart-Porter","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.11.052_b0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/cid\/cis384","article-title":"Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations","volume":"55","author":"Uwanyiligira","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.11.052_b0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a Phase 2\/3, randomized, single-blind, noninferiority","volume":"66","author":"Gogtay","year":"2018","journal-title":"Controlled Study Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.11.052_b0155","first-page":"13","article-title":"Challenges of Rabies Serology: Defining Context of Interpretation","author":"Moore","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2023.11.052_b9000","doi-asserted-by":"crossref","first-page":"2275453","DOI":"10.1080\/21645515.2023.2275453","article-title":"Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults","volume":"19","author":"Pichon","year":"2023","journal-title":"Hum Vaccin Immunother."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23013981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23013981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:29:38Z","timestamp":1729139378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23013981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X23013981"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.11.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax\u00ae Rabies) administered in a simulated rabies post-exposure regimen in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.11.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}